Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Dipharma","sponsor":"Analog Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analog Pharma and Dipharma Announce US FDA Approval of Abbreviated New Drug Application (ANDA) of 20 mg Generic Nitisinone Capsules (temperature stable)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Dipharma

    Menu

    Dipharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dipharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Analog Pharma and Dipharma Announce US FDA Approval of Abbreviated New Drug Application (ANDA) of 20 mg Generic Nitisinone Capsules (temperature stable)

              Details:

              Orfadin (nitisinone) is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1.

              Lead Product(s): Nitisinone

              Therapeutic Area: Genetic Disease Product Name: Orfadin-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Analog Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY